Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression.

31 Mar 2014

Seroxat in combination with acupuncture produces significant effect in patients with unipolar depression

Acupuncture is more effective than oral antidepressants in improving depressive symptoms, and produces fewer side effects than tricyclic antidepressants.

28 Mar 2014

New report provides link between poor health and multiple forms of discrimination

Racial and sexual minorities, women, and obese people may face more health risks because of their disproportionate exposure to discrimination, according to a new report in the Journal of Health and Social Behavior.

26 Mar 2014

Adolescence is key developmental period for obesity and depression

Depression and obesity have long been associated, but how they relate over time is less clear. New research from a Rutgers University-Camden professor shows that adolescent females who experience one of the disorders are at a greater risk for the other as they get older.

24 Mar 2014

Illness course impacts suicide risk in bipolar and depressive disorder

Differing illness course, rather than the illness itself, is the greatest determinant of the differential risk of suicide attempts between patients with bipolar disorder and those with major depressive disorder, study findings indicate.

20 Mar 2014

Researchers examine effect of vitamin D supplementation on depression

Vitamin D deficiency has been implicated in numerous health conditions in recent years, including depressed mood and major depressive disorder.

19 Mar 2014

Neuralstem announces results from Phase I trial using NSI-566 spinal cord stem cells in treatment of ALS

Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were published in the peer-reviewed journal, "Annals of Neurology".

18 Mar 2014

Frontal lobe atrophy identified in poor sleepers

US researchers have used neuroimaging to show that war veterans with poor sleep quality have reduced frontal lobe volumes.

17 Mar 2014

Alkermes initiates pivotal clinical development program for treatment of MDD

Alkermes plc today announced the initiation of the pivotal clinical development program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).

6 Mar 2014

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease.

4 Mar 2014

Naurex's GLYX-13 receives FDA Fast Track designation

Naurex Inc. today announced that the U.S. Food and Drug Administration has granted Fast Track designation to the investigation of GLYX-13, the company's rapid-acting antidepressant in Phase 2 clinical development, as adjunctive therapy in major depressive disorder.

4 Mar 2014

BDNF abnormalities may predict bipolar disorder

Patients with bipolar disorder show abnormalities in the conversion of pro-brain derived neurotrophic factor to the mature form, which may be used to aid diagnosis of the condition.

28 Feb 2014

How do people become depressed? An interview with Anna Watters and Professor Lea Williams, University of Sydney

A clinical diagnosis of depression (i.e. major depressive disorder) is currently defined on the basis of reported symptoms.

19 Feb 2014

Urinary tract infections linked to acute psychosis relapse

Patients with an acute episode of psychosis have a high incidence of urinary tract infections, report researchers.

12 Feb 2014

Simple hypomania checklist detects bipolar II disorder

A 15-item hypomania checklist has shown potential for differentiating bipolar disorder, particularly type II, from major depressive disorder.

30 Jan 2014

Continuity of care protects mental health patients

Research shows that seeing the same psychiatrist over time is associated with reduced mortality in patients using mental health services, particularly those with bipolar disorder, major depressive disorder, or schizophrenia.

28 Jan 2014

Cortical thickness may distinguish bipolar from unipolar disorder

Patients with depression have areas of reduced cortical thickness, with clear distinctions between those with bipolar disorder and major depressive disorder, report US researchers.

23 Jan 2014

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, announced that reported diluted earnings per share equaled $0.07 in the third quarter of fiscal 2014, compared to a reported loss per share of ($0.58) in the third quarter of fiscal 2013. The third quarter of fiscal 2014 included a $45 million charge ($28.2 million net of tax) related to Project Rejuvenate.

21 Jan 2014

Emotion regulation deficits characterize bipolar and MDD patients

Patients with bipolar disorder and major depressive disorder have increased use of maladaptive and decreased use of adaptive emotion regulation strategies, researchers report.

15 Jan 2014

Study finds discrepancies in prevalence estimates of mental disorders in middle-aged and older adults

Common methods of assessing mental or physical disorders may consistently underestimate the prevalence of mental disorders among middle-aged and older adults, a new study from the Johns Hopkins Bloomberg School of Public Health has found.

9 Jan 2014